We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sagiment Biosciences Inc | NASDAQ:SGMT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.08 | -1.58% | 4.99 | 4.35 | 6.67 | 5.25 | 4.92 | 4.9278 | 414,512 | 05:00:09 |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
_________________ | |
SCHEDULE 13G/A | |
Under the Securities Exchange Act of 1934 | |
(Amendment No. 1)* | |
Sagimet Biosciences Inc. | |
(Name of Issuer) | |
Series A Common Stock, par value $0.0001 per share | |
(Title of Class of Securities) | |
786700104 | |
(CUSIP Number) | |
September 30, 2024 | |
(Date of Event Which Requires Filing of this Statement) | |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: | |
¨ | Rule 13d-1(b) |
ý | Rule 13d-1(c) |
¨ | Rule 13d-1(d) |
(Page 1 of 7 Pages) |
______________________________
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 786700104 | 13G/A | Page 1 of 7 Pages |
1 |
NAME OF REPORTING PERSON
Point72 Asset Management, L.P. | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨ (b) x | ||
3 | SEC USE ONLY | |||
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 |
SOLE VOTING POWER 0 | ||
6 |
SHARED VOTING POWER 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
7 |
SOLE DISPOSITIVE POWER 0 | |||
8 |
SHARED DISPOSITIVE POWER 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.0% | |||
12 |
TYPE OF REPORTING PERSON PN | |||
CUSIP No. 786700104 | 13G/A | Page 2 of 7 Pages |
1 |
NAME OF REPORTING PERSON
Point72 Capital Advisors, Inc. | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨ (b) x | ||
3 | SEC USE ONLY | |||
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 |
SOLE VOTING POWER 0 | ||
6 |
SHARED VOTING POWER 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
7 |
SOLE DISPOSITIVE POWER 0 | |||
8 |
SHARED DISPOSITIVE POWER 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.0% | |||
12 |
TYPE OF REPORTING PERSON CO | |||
CUSIP No. 786700104 | 13G/A | Page 3 of 7 Pages |
1 |
NAME OF REPORTING PERSON
Steven A. Cohen | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨ (b) x | ||
3 | SEC USE ONLY | |||
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 |
SOLE VOTING POWER 0 | ||
6 |
SHARED VOTING POWER 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
7 |
SOLE DISPOSITIVE POWER 0 | |||
8 |
SHARED DISPOSITIVE POWER 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options) | |||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.0% | |||
12 |
TYPE OF REPORTING PERSON IN | |||
CUSIP No. 786700104 | 13G/A | Page 4 of 7 Pages |
Item 1(a). | Name of Issuer. |
Sagimet Biosciences Inc. (the “Issuer”). |
Item 1(b). | Address of Issuer’s Principal Executive Offices. |
155 Bovet Road, Suite 303, San Mateo, CA 94402. |
Item 2(a). | Name of Person Filing. |
This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of Series A common stock, par value $0.0001 per share (“Series A Common Stock”), of the Issuer held by (and underlying options held by) Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Series A Common Stock held by (and underlying options held by) Point72 Associates; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Series A Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. |
Item 2(b). | Address of Principal Business Office. |
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902. |
Item 2(c). | Place of Organization. |
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen. |
Item 2(d). | Title of Class of Securities. |
Series A Common Stock, par value $0.0001 per share. |
Item 2(e). | CUSIP Number. |
786700104 |
Item 3. | If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: |
Not applicable. | |
CUSIP No. 786700104 | 13G/A | Page 5 of 7 Pages |
Item 4. | Ownership. |
The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on September 30, 2024. | |
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Series A Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Series A Common Stock reported herein. |
Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. |
Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Series A Common Stock. |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not applicable. |
Item 8. | Identification and Classification of Members of the Group. |
Not applicable. |
Item 9. | Notice of Dissolution of Group. |
Not applicable. |
Item 10. | Certification. |
By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. | |
CUSIP No. 786700104 | 13G/A | Page 6 of 7 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Date: November 14, 2024 | ||
POINT72 ASSET MANAGEMENT, L.P. | ||
By: |
/s/ Jason M. Colombo | |
Name: Jason M. Colombo | ||
Title: Authorized Person | ||
POINT72 CAPITAL ADVISORS, INC. | ||
By: |
/s/ Jason M. Colombo | |
Name: Jason M. Colombo | ||
Title: Authorized Person | ||
STEVEN A. COHEN | ||
By: |
/s/ Jason M. Colombo | |
Name: Jason M. Colombo | ||
Title: Authorized Person | ||
1 Year Sagiment Biosciences Chart |
1 Month Sagiment Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions